STING1 and breast cancer: In mouse models of breast cancer, lung cancer, and melanoma, administration of low doses of STING agonists like cGAMP and ADU-S100 has demonstrated a synergistic effect in promoting tumor-associated vascular normalization, recruiting circulating immune cells, and facilitating endothelial adhesion.48, 49, 50 This process enables the infiltration of tumor-infiltrating lymphocytes into the TME, laying the groundwork for the formation of tertiary lymphoid structures (TLS).